These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 1999720)

  • 1. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
    Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
    J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
    Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
    J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
    Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
    Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
    Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
    Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
    Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
    Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
    Poplin EA; Corbett T; Flaherty L; Tarasoff P; Redman BG; Valdivieso M; Baker L
    Invest New Drugs; 1992 Aug; 10(3):165-70. PubMed ID: 1428726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
    Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
    Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
    Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
    Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
    Brand R; Capadano M; Tempero M
    Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
    Buesa JM; Losa R; Fernández A; Sierra M; Esteban E; Díaz A; López-Pousa A; Fra J
    Cancer; 2004 Nov; 101(10):2261-9. PubMed ID: 15484216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
    Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
    Freise KJ; Martín-Jiménez T
    J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
    Reid JM; Qu W; Safgren SL; Ames MM; Krailo MD; Seibel NL; Kuttesch J; Holcenberg J
    J Clin Oncol; 2004 Jun; 22(12):2445-51. PubMed ID: 15197207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
    Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
    Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.